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Abstract 
Objective To determine the effectiveness of prescribing 2 g plant sterols/stanols per day as an addition to 
standard practice in a dietary outpatient clinic. Design A randomized parallel design of comparative 
12-week interventions. Subjects/Setting Patients referred by a general practitioner to a dietary outpatient 
clinic for the management of hyperlipidemia were eligible. Twenty-five patients (15 women and 10 men) 
completed the study. Intervention Counselling regarding diet for hyperlipidemia was based on the 
National Cholesterol Education Program (NCEP) guidelines. The intervention group was instructed to 
incorporate ~25 g/day of margarine containing plant sterols/stanols, which delivered ~2 g of plant 
sterols/stanols. Main outcome measure Changes in diet, body weight and serum total cholesterol, LDL 
cholesterol, HDL cholesterol and triglycerides. Statistical analysis performed Changes in dietary and 
biochemical outcomes were assessed using Student’s t-test. For non-normally distributed data, Wilcoxon 
signed rank test was used and Mann-Whitney U tests were conducted to determine the proportion of 
subjects reaching defined goals. The number needed to treat (NNT) index was used to report 
effectiveness of the intervention. Results Five of 14 subjects in the intervention group compared to 0 of 
11 in the control group achieved a reduction in serum cholesterol of ≥ 15% (P < .05). Using the NNT index, 
for each 2.8 patients counselled with routine prescription of plant sterols/stanols, one additional patient 
would obtain a reduction in cholesterol by ≥ 15% compared with conventional management. This was 
achieved without any detrimental effects on the dietary fatty acid profile. Application/conclusion Routine 
prescription of margarine containing plant sterol/stanol is an effective strategy in the management of 
hypercholesterolemic patients in the clinical setting. 
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Plant sterol/stanol prescription is an effective treatment strategy for managing 
hypercholesterolemia in outpatient clinical practice 
 
Abstract   
 
Objective To determine the effectiveness of prescribing 2 g plant sterols/stanols per day as an addition 
to standard practice in a dietary outpatient clinic. 
Design A randomized parallel design of comparative 12-week interventions. 
Subjects/Setting Patients referred by a general practitioner to a dietary outpatient clinic for the 
management of hyperlipidemia were eligible. Twenty-five patients (15 women and 10 men) completed 
the study.   
Intervention Counselling regarding diet for hyperlipidemia was based on the National Cholesterol 
Education Program (NCEP) guidelines.  The intervention group was instructed to incorporate ~25 
g/day of margarine containing plant sterols/stanols, which delivered ~2 g of plant sterols/stanols. 
Main outcome measure Changes in diet, body weight and serum total cholesterol, LDL cholesterol, 
HDL cholesterol and triglycerides. 
Statistical analysis performed Changes in dietary and biochemical outcomes were assessed using 
Student’s t-test.  For non-normally distributed data, Wilcoxon signed rank test was used and 
Mann-Whitney U tests were conducted to determine the proportion of subjects reaching defined goals.  
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The number needed to treat (NNT) index was used to report effectiveness of the intervention. 
Results Five of 14 subjects in the intervention group compared to 0 of 11 in the control group achieved 
a reduction in serum cholesterol of ≥ 15% (P < .05).  Using the NNT index, for each 2.8 patients 
counselled with routine prescription of plant sterols/stanols, one additional patient would obtain a 
reduction in cholesterol by ≥ 15% compared with conventional management. This was achieved 
without any detrimental effects on the dietary fatty acid profile.   
Application/conclusion Routine prescription of margarine containing plant sterol/stanol is an effective 
strategy in the management of hypercholesterolemic patients in the clinical setting. 
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Plant sterol/stanol prescription is an effective treatment strategy for managing 
hypercholesterolemia in outpatient clinical practice 
 
INTRODUCTION 
 
Forty-one clinical trials have studied the efficacy of plant sterol esters and plant stanol esters in 
reducing mean total cholesterol (TC) and low-density lipoprotein cholesterol (LDL)1. When plant 
sterols/stanols are added to foods such as margarine, up to a 15% reduction in serum TC and LDL has 
been reported and the effect is additive with diet and drug interventions1. To this end the Adult 
Treatment Panel (ATP III) of the National Cholesterol Education Program (NCEP) recommend the 
addition of plant sterols (2g/day) to the diet2. However, all studies to date have been in controlled 
settings using willing volunteers and providing subjects with sterol containing products.  These results 
are yet to be replicated in subjects who assemble the diets for themselves on a routine basis, thus 
determining the true effectiveness of this strategy in the clinical setting 3.
It is commonplace when determining evidence for functional foods to equate efficacy with 
effectiveness.  Whereas efficacy aims to establish a relationship between a bioactive component and a 
therapeutic benefit, effectiveness goes one step further in answering the question of compliance i.e. do 
subjects comply with the therapy and does the therapeutic relationship hold.  Whilst it may be correct 
5
to assume that efficacy often equates to effectiveness with therapeutic drugs, with functional foods, 
issues relating to the belief in the benefit of use, taste, preference and price may affect intake and 
ultimately compliance 4, 5. In addition, the net effect on the whole diet needs to be considered in those 
who select functional foods, given the importance of other dietary aspects such as restricting saturated 
fat and cholesterol and increasing omega-3 fatty acids, in reducing CHD risk6. It is therefore 
important in evaluating effectiveness to design trials in free-living contexts. 
 
A clinical setting with standard practices is a useful setting for this research.  However, the problem 
associated with recruitment in clinical trials has been acknowledged in the literature and obtaining the 
numbers needed to achieve statistically significant results can be problematic7. The Number Needed 
to Treat (NNT) is becoming increasingly popular as an index for reporting results of randomized 
controlled trials and other clinical trials8. The NNT represents the clinical effort that is required by 
treatment in order to achieve a positive outcome, compared to the expected response in a control group.  
This provides a useful measure of effectiveness and overcomes some of the issues of recruitment of 
large numbers of subjects. 
 
To test the effectiveness of plant sterol/stanol prescription, we randomised consenting patients in an 
outpatient nutrition clinic to either standard practice (a low fat, low saturated fat, high fibre diet) or 
standard practice with the additional prescription of 25g of a plant sterol or plant stanol containing 
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margarine.  This was a free-living trial.  No food products were supplied to subjects, and the 
margarines prescribed were available commercially. 
 
SUBJECTS AND METHODS 
Participants and Study Design 
Subjects were recruited through an established dietary outpatient clinic over an 18-month period, from 
February 2001 to August 2002.  Subjects were included if they were aged between 30-75 years and 
had a fasting serum total cholesterol concentration > 5.5mmol/L.  Those who were of non-English 
speaking background, taking lipid lowering medication for less than 3 months prior to referral or had 
changed dosage within the last 3-month period were excluded, along with subjects following dietary 
regimens for allergy or intolerance, renal disease and diabetes mellitus.  Details of the study were 
explained to all subjects and written informed consent provided before participation in the study.  The 
goal was to recruit 80 participants (allowing for 10 drop outs), on a sequential basis using a blocking 
protocol for total serum cholesterol to ensure the cholesterol levels at baseline did not differ between 
the groups.  Within each block, the allocation to treatment or control group was random.  The study 
was conducted on an outpatient basis over 12 weeks and no foods or supplements were provided to 
subjects.  At baseline (week 0) and week 12 subjects filled out a 3-day food record (two week days 
and 1 weekend day).  One week later (week 1 and 13) a detailed dietary history was conducted along 
with weight, waist circumference measurement and an activity questionnaire.  Fasting blood samples 
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were collected prior to baseline ~2-3 weeks and at 12 weeks.    The human research ethics committee 
of the University of Wollongong and the Illawarra Area Health Service approved the study. 
 
Treatment Conditions 
Control group 
Subjects were individually instructed by the same Accredited Practicing Dietitian to consume a diet low 
in saturated fat, consistent with the Therapeutic Lifestyle Changes dietary approach as outlined by 
NECP 2. In summary, the diet aims for 25 - 30% of total calories from fat (<7% saturated fatty acids, 
up to 10% polyunsaturated fatty acids, and up to 20% monounsaturated fatty acids), 50 - 60% of total 
calories from carbohydrates, ~ 15% of total energy from protein, <200mg cholesterol/day, fibre 
20 –30g/day and total energy to balanced with energy expenditure to maintain desirable body weight or 
prevent weight gain 2. Sterol/stanol use was not included as part of dietary instruction, however if 
subjects were currently using plant sterol/stanol containing margarine they were encouraged to 
continue.  This was regarded as standard practice and there would be ethical implications to actively 
discouraging the use of these products.  Subjects were provided with information sheets offering 
practical suggestions and an individual diet plan.  Furthermore, all subjects were encouraged to 
exercise (eg 30-minute brisk walking) at least 3 sessions per week.  Counselling sessions consisted of 
a 1-hour session at week 1 and two 30-minute sessions at week 3 and 6. 
Intervention group 
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The intervention diet was identical to the control diet in all but one aspect.  All subjects on the 
intervention diet were instructed to consumer 25g (5 teaspoons) of either Flora’s Pro-active or 
Meadow Lea’s Logicol margarine (these were the only plant sterol and plant stanol containing 
products respectively on the Australian market at the time of the study).  The information sheets and 
diet plans explicitly stated these products and the amount to be consumed each day.  Subjects were 
instructed to modify their fat intake to accommodate the sterol/stanol dosing and encouraged to 
consume additional carotenoid containing vegetables to prevent a possible decrease in plasma 
carotenoids as a result of the sterol/stanol intake 9. This message was the focus of each follow-up 
clinic visit. 
 
Dietary Measurement 
A dietary history (DH) interview was conducted by the same dietitian (CP) at baseline and at 12 weeks.  
The DH method lends itself well to clinical practice where it provides clinicians with and opportunity 
to subjectively examine meal patterns and provide dietary advice while the patient is still present 10.
Furthermore the utility of this method has been demonstrated in a number of sample groups, including 
short-term intervention studies 11,12,13. The approach taken was a narrative style DH interview 
(open-ended) described in detail elsewhere11. In summary, the meal based diet history interview noted 
the types, amounts and frequency of consumption of all foods consumed routinely within a 3-month 
reference time. The interview was completed with a food frequency checklist of major food categories, 
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snack and drink items (including alcohol), and sources of omega 3 fatty acids (fish, nuts, soy foods), as 
well as questions on food preparation practices. The same assessor was the interventionist in this 
study; therefore the DH was not blinded.   Subjects were also required to keep an estimated 3-day 
food record (FR) (two weekdays and one weekend day) after the collection of the DH.  Forms were 
provided along with instructions on how to estimate food portion sizes using standard kitchen 
measuring equipment.  Food records were checked for missing values and clarification.   
 
Anthropometric Measurement 
Weight and height was recorded at each interview using calibrated balance scales and a wall mounted 
stadiometer.  All subjects were clothed (light shirt).  Height was measured to the nearest 0.5cm and 
weight to the nearest 0.1kg.  Waist and hip circumferences were measured at each time point.  Waist 
circumference was measured using a standard cloth measuring tape (units in centimetres and inches); 
with measurements made halfway between the lower border of the ribs, and the iliac crest in a 
horizontal plane.  Hip circumference was measured at the widest point over the buttocks.  For each 
circumference, measurements were recorded to the nearest 0.5 cm.  Activity level was obtained from a 
self-reported description of usual activity, including details of number of sessions a week of activity, 
the duration of each session and the intensity of each activity. 
 
Biochemical Measurement 
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In keeping with standard clinical practice, a trained phlebotomist at accredited pathology laboratories 
within the Illawarra region (Southern IML Pathology) drew blood samples from subjects after an 
overnight fast.  Subsequently, samples were analysed for concentrations of total cholesterol, HDL 
cholesterol, LDL cholesterol, and triacylglycerol.  The pathology laboratories were fully accredited 
with the National Association of Testing Authorities (NATA) and the Royal College of Pathologists of 
Australasia (RCPA), which is a mandatory requirement for pathology laboratories in Australia. 
 
Analysis and Statistics 
Dietary data were analysed with Foodworks nutrient analysis software package (Professional Version 
3.1, Xyris Sortware, Highgate Hill, Brisbane Australia), which is based on the Australian Nutrient 
Database (AUSNUT 2000, Department of Human Services and Health, Canberra).  
 
The required sample calculation of n = 80 was based on detecting a difference in TC between the 
groups of 10% at 80% power.  A Bland Altman plot 14 was prepared to determine possible bias 
between actual and recalled total fat (%kcal) with the two dietary assessment methods.  As described 
by Bland and Altman 14 the average of the reported fat intake in the DH and the FR (x axis) are plotted 
against the difference between the DH and FR recorded fat intake (y axis).  The limits of agreement 
were set at 2 SD of the difference above and below the mean.  Comparing the reported intake using 
the DH and FR using Pearson’s correlation coefficient assessed the validity of sterol/stanol intake.  
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Changes between week 0 and week 12 were studied for all variables.  Dietary data and baseline 
measurements were assessed using a two-factor analysis of variance with diet and sex as fixed factors.  
The effect of dietary intervention was assessed using paired Student’s t-tests when comparing the 
change in variables (dietary, anthropometric and biochemical data) between groups.  For 
non-normally distributed data, Wilcoxon signed ranks test was used for within group comparisons, and 
Mann-Whitney U test were conducted to determine the proportion of subjects reaching dietary and 
biochemical goals between the groups.  Changes in clinical outcomes were analysed with an intention 
to treat model-using analysis of variance i.e. subjects were included in the analysis whether or not they 
consumed the prescribed dose of plant sterol/stanol.   The relationship between plant sterol intake and 
serum cholesterol was determined using Pearson’s correlation coefficient.  The number needed to treat 
(NNT) index as described elsewhere was used to report effectiveness of the intervention 8. The NNT 
was calculated using the proportions of subjects on the control or experimental treatment who achieve a 
total cholesterol reduction of ≥ 15%.  NNT is defined as8:
Here π1 and π2 are defined as the proportions of subjects on the control or experimental treatment 
(respectively) that experience the defined outcome.  
π1 - π2
1NNT =
12
 
A P - value less than .05 were considered to be statistically significant. SPSS for Windows (version 
10.0, 1999, Chicago, IL) was used for all statistical analyses. 
RESULTS 
 
Subject demographics 
During the 18-month time course of the study forty-two participants met the eligibility criteria, 32 
agreed to participate producing a group randomisation of 15 control and 17 intervention subjects.  
Twenty-five subjects (15 women, 10 men) completed the study producing a group randomisation of 11 
control and 14 intervention subjects.  One subject withdrew after a myocardial infarct, another subject 
was hospitalised for psychiatric illness and was unable to complete the final assessment phase, the 
clinic lost contact with another subject, and four withdrew after the initial assessment.  Baseline 
characteristics of all subjects admitted to the study are shown in Table 1.  The groups did not differ in 
terms of age, sex, body mass index, level activity, waist:hip ratio, medication use, or serum lipid levels.   
[INSERT Tab 1] 
 
Dietary data 
Using the Bland-Altman plot there was no relationship between the average of the reported fat intake 
using DH and FR with the difference between the two methods (Figure 1).  All but one value was 
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within the 2 SD confidence limits as recommended by Bland and Altman14 indicating that there was no 
systematic bias.  Strong correlations were found between the DH and FR method (r = 0.782, P<.001) 
for plant sterol/stanol consumption.  Results of the dietary analyses using DH data are reported in 
Table 2.  Overall, nutrient intakes were not significantly different between the two groups at baseline 
and at the end of the study (12 weeks).  However, the change in protein was higher in the intervention 
group (22%) compared to the control group (5%) as well as the change in alcohol intake (-7g/day, 
2g/day in the intervention and control group respectively).  The average intake of plant sterols/stanols 
increased by 1.3g/day in the intervention group and reduced by 0.3g/day in the control group (P<.05), 
and 20% achieved the goal intake of ≥ 2g/day compared to none in the control (P<.05).  After the 
intervention period, 43% (P<.05) of the intervention subjects achieved a polyunsaturated fat intake 
within the NCEP Step 1 diet recommendations (≥ 7%kcal) whereas none achieved this goal in the 
control.  There were no other differences between the groups in achieving the NCEP 
recommendations (Table 3).  
 [INSERT Fig 1] 
 [INSERT Tab 2] 
 [INSERT Tab 3] 
 
Serum lipids in response to treatment 
Total cholesterol, plasma triacylglycerol, HDL cholesterol and LDL cholesterol concentrations did not 
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differ significantly over time or between groups.  Concentrations of plasma lipids at the beginning and 
end of the trial are shown in Table 4.  After the 12-week intervention the reductions in total 
cholesterol and LDL cholesterol were more than double in the intervention group compared to the 
control group, but these differences did not reach statistical significance.  There was a strong inverse 
relationship between 12-week dietary sterol/stanol intake and change in serum cholesterol (r = -.62; P
= .001) and serum LDL cholesterol ( r= -.58; P = .019). 
[INSERT Tab 4] 
 
Clinical indexes 
At the completion of the 12-week study 5 of 14 subjects in the intervention group achieved ≥ 15%
change in total cholesterol compared to 0 of 11 in the control (P <.05).  No other significant changes 
were observed between the groups.  Both groups showed a mean weight change of < 1.0 kg and there 
were no significant differences in body weight from the baseline to the end of the study.  The NNT 
was calculated to be 2.8.   
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DISCUSSION 
 
This present study is the first, to our knowledge, investigating the utility of using plant sterol/stanol 
enriched margarine in a free-living clinical context.  While evidence-based nutrition recommendations 
attempt to translate research data into nutrition care15, research in clinical settings are paramount, as the 
applicability of controlled studies to the general community is often questioned16. For example, in the 
effective management of hyperlipidemia there are a number of dietary approaches that can achieve 
moderate results; these include reducing the saturated fat in the diet, increasing omega-3 
polyunsaturated diet and increasing dietary fibre17. It is important that the introduction of novel 
dietary strategies do not adversely affect the dietary profile.   
 
In conjunction with dietary advice consistent with the NCEP guidelines, we found that the inclusion of 
~1.5-2g/d of plant sterol in margarine did not adversely affect the dietary fat or plasma lipid profiles 
(Tables 2 and 4).  Of particular interest was the increase in the proportion of fats coming from 
polyunsaturated fat in the intervention group.  Intervention trials have shown that visible fats (such as 
margarine and nuts) are often excluded from the diet in preference to hidden fats that are often 
saturated 18. The net effect is an decrease in the P:S ratio.  There is increasing evidence of the 
importance of polyunsaturated fats as an important dietary component in reducing the risk of CVD and 
the need to increase the P:S ratio is of importance19. A serendipitous result of prescribing a daily dose 
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of plant sterol/stanol enriched margarine was the delivery of extra omega-3 polyunsaturated fatty acids.  
As plant sterols/stanols have an additive effect with other dietary modifications20, prescribing enriched 
margarine is an effective strategy to achieve both of these targets. 
 
Our dietary assessment measures had some limitations.  In our pursuit of designing a study resembling 
‘real life’ conditions there was a trade off by un-blinding the DH, as the assessor was also the 
interventionist.  The impact of this on our interpretation of results is marginal as we demonstrated 
strong agreement between the DH and FR methods for dietary fats and sterol/stanols indicating relative 
validity.  
 
Although compliance to the dietary regimen is a key component of determining effectiveness, the 
ability to show the therapeutic benefit is also important.  The mean percent reduction in total 
cholesterol and LDL cholesterol in the intervention group was ~11% and ~12% respectively compared 
to ~5% and ~4% in the control group.  This difference however was not statistically significant either 
within groups or between groups over time, probably because our final sample size was significantly 
smaller (n=25) compared to our original sample size power calculations (n=80).  The study was 
underpowered to reject the null hypothesis that is, there was not have enough evidence to say there was 
a significant difference between the groups.   
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Our results show that dietary prescription of plant sterol/stanol margarines in conjunction with the 
NECP guidelines for the management of blood lipids resulted in an intake of 1.3g sterol/day, whereas 
in the control group plant sterols reduced their intake by 0.4g/day.  Although studies have shown that 
2g/day of plant sterol is the therapeutic optimal dose, the response curve is linear suggesting that an 
intake of around 1.5g/day is still clinically useful and the levels achieved would be predicted to achieve 
a change of ~10% in total serum cholesterol and LDL cholesterol20.
A significant limitation to clinical practice in the dietary management of hyperlipidemia is that despite 
studies in controlled environments achieving up to 15% reductions in total cholesterol, results in a 
free-living context have at best have shown a 5% reduction 21. We observed that 5 of 11 (36%) in the 
intervention group achieved a reduction in serum cholesterol levels ≥ 15% compared to none in the 
control.  This has an important clinical implication, which can be summarised using the NNT statistic.  
Using this index we can predict that if clinicians routinely prescribe 2g/day of plant sterol/stanol 
margarine, then for every 2.8 patients given this advice an extra patient will achieve a cholesterol 
reducing effect ≥ 15%, compared to a more conventional approach to dietary therapy.  However, these 
results can only be viewed as preliminary at this stage as the small sample size makes generalizing 
beyond the bounds of this clinical context inappropriate.  Further research is required in this area 
which would involve a larger sample, drawn over multiple clinical sites before conclusive evidence can 
be provided. 
18
 
CONCLUSION/APPLICATIONS 
 
What we have known for many years regarding the efficacy of plant sterol/stanol enriched food 
products in the management of hyperlipidemia can now be extrapolated into a free-living, context.  
Plant sterol/stanol margarines provide a useful and significant adjunct to medical nutrition therapy.  
However, while these results may be relevant when considering other functional ingredients added to 
margarine, the value of other functional foods on the dietary profile would need studies specifically 
designed to examine the effects in a true to life situation3. Only at this point can we truly assess the 
effectiveness of functional food products on health outcomes. 
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Table 1 Participant characteristics at baseline  
 Control Group 
(n=15) 
Intervention 
Group 
(n=17) 
Age (y) (mean ± SD) 59.2 (±13.2) 55.2 (±13.4) 
Female/Male 11/4 8/9 
BMI (kg/m2) (mean ± SD) 29.8 (±3.3) 31.4 (±5.9) 
Waist/Hip ratio (mean ± SD) 0.92 (±0.1) 0.94 (±0.12) 
Cholesterol lowering medication (n)† 2 3
Frequency of activity 
 Nil 
 1-2 times per week 
 3-4 times per week 
 5-6 times per week 
 >6/7 times per week  
 
5
3
2
1
0
6
3
2
2
1
Total cholesterol (mmol/L) (mean ± SD) 
*LDL cholesterol (mmol/L) (mean ± SD) 
**Triacylglycerol (mmol/L) (mean ± SD) 
***HDL cholesterol (mmol/L) (mean ± SD) 
6.64 (±0.8) 
4.25 (±0.6) 
2.40 (±1.4) 
1.27 (±0.3) 
6.89 (±1.1) 
4.35 (±0.8) 
2.28 (±1.1) 
1.26 (±0.3) 
*n =23, **n = 30, ***n = 27 
There were no significant differences between any of the groups at baseline using Student’s t-test for normally distributed 
data and Wilcoxan sign ranked test for categorical data. 
†Refers to number of patients taking cholesterol lowering medication who had not reported a change in dose for >3 months.
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Figure 1 Bland-Altman plot of the mean difference between the DH and FR for fat (%kcal) versus the mean of the DH and 
FR, with limits of agreement 2 SD from the mean difference. 
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Table 2 Mean (±SD) of dietary composition at week 0 and 12 as determined by DH. 
 
Lipid Control group 
(n=11 ) 
Intervention group 
(n=14) 
Energy   
Week 0 (kcal) 1928 (±636) 2129 (±789) 
 Week 12 (kcal) 1842 (±573) 1727 (±411)  
 ^Change % -4.5 (±21) -18.9 (±30) 
Protein   
 Week 0 (%kcal) 19.7 (±2.3) 17.2 (±3.2) 
 Week 12 (%kcal) 20.7 (±2.0) 21.0 (±3.0) 
 ^Change % 5.2 (±13.8) * 21.9 (±21.4) * 
Fat   
 Week 0 (%kcal) 29.7 (±5.3) 31.9 (±8.9) 
 Week 12 (%kcal) 27.4 (±5.4) 29.9 (±6.4) 
 ^Change % -8.0 (±14.8) -6.4 (±34.3) 
CHO   
 Week 0 (%kcal) 47.4 (±4.8) 44.4 (±6.8) 
 Week 12 (%kcal) 48.0 (±4.7) 44.1 (±7.0) 
 ^Change % 1.2 (±8.7) -0.7 (±31.2) 
SFA   
 Week 0 (%kcal) 10.1 (±2.9) 10.9 (±6.9) 
 Week 12 (%kcal) 8.0 (±2.3) 7.3 (±2.1) 
 ^Change % -20.8 (±27.5) -32.1 (±37.5) 
MUFA   
 Week 0 (%kcal) 12.4 (±2.6) 12.9 (±3.3) 
 Week 12 (%kcal) 11.7 (±2.6) 13.3 (±3.6) 
 ^Change % -5.6 (±17.8) 2.9 (±37.9) 
PUFA   
 Week 0 (%kcal) 4.4 (±1.1) 5.3 (±1.5) 
 Week 12 (%kcal) 4.0 (±1.2) 6.3 (±2.4) 
 ^Change % 10.1 (±32.4) 18.6 (±56.2) 
Cholesterol   
 Week 0 (mg) 201.3 (±106.4) 236.7 (±166.1) 
 Week 12 (mg) 170.8 (±58.4) 153.1 (±64.9) 
 ^Change % -15.1 (±34.6) -35.3 (±41.4) 
Dietary fibre   
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 Week 0 (g/day) 28.5 (±10.1) 24.2 (±8.5) 
Week 12 (g/day) 35.3 (±17.3) 26.5 (±8.9) 
 ^Change % 24.1 (±69.4) 9.5 (±40.9) 
Alcohol   
 Week 0 (g/day) 3.4 (±6.1) 15.2 (±24.1) 
 Week 12 (g/day) 5.6 (±8.8) 8.4 (±16.7) 
 ^^Change (g/day) 2.2 (±3.9) * -6.8 (±10.7) * 
Sterol/stanol intake   
 Week 0 (g/day) 0.8 (±1.0) 0.2 (±0.5) 
 Week 12 (g/day) 0.5 (±0.8) 1.5 (±0.8) 
 ^^Change (g/day) -0.32 (±0.7) * 1.26 (±0.9) * 
*P<.05, **P<0.01, significantly different between the groups 
^Change % =                     X 100%.   
^^Change =                      
week 0 
week 12 – week 0 
week 12 – week 0 
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Table 3  Number of subjects meeting selected fatty acid targets at baseline and 12 weeks (n = 25). 
Time Group Plant sterol/stanol Saturated fat intake Polyunsaturated fat intake 
≥ 2g/day < 2g/day ≥ 10%kcal < 10%kcal ≥ 7%kcal < 7%kcal 
Baseline Control 0 0 4 7 0 11 
Intervention 0 0 7 7 2 12 
12 weeks Control 0* 11 2 9 0* 11 
 Intervention 3* 11 2 12 6* 8
*P<.05, **P<.01, significantly different between the groups, Mann-Whitney U Test. 
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Table 4 Mean (±SD) plasma lipid concentrations on week 0 and 12 with each dietary intervention. 
Lipid Control group  Intervention group) 
Total cholesterol   
Week 0 (mmol/L) 6.64 (±0.8) 6.89 (±1.1) 
 Week 12 (mmol/L) 6.29 (±0.7) 6.10 (±1.0) 
 Change % -5.3 (±11.5) -11.5 (±13.9) 
LDL cholesterol (n = 17)   
 Week 0 (mmol/L)  4.25 (±0.6) 4.35 (±0.8) 
 Week 12 (mmol/L)  4.06 (±0.9)  3.82 (±0.9)  
 ^Change %  -4.5 (±15.7) -12.2 (±13.1) 
Triacylglycerol (n = 24)   
 Week 0 (mmol/L)  2.40 (±1.4) 2.28 (±1.1) 
 Week 12 (mmol/L)  2.20 (±1.3) 2.20 (±0.9) 
 ^Change %  -8.3 (±28.7) -3.5 (±34.7) 
HDL cholesterol (n = 19)   
 Week 0 (mmol/L)  1.27 (±0.3) 1.26 (±0.3) 
 Week 12 (mmol/L)  1.29 (±0.3) 1.27 (±0.3) 
 ^Change % 1.6 (±8.7) 0.7 (±13.1) 
LDL:HDL ratio (n = 18)   
 Week 0 (mmol/L)  3.37 (±0.9) 3.49 (±1.0) 
 Week 12 (mmol/L)  3.29 (±1.1) 3.21 (±1.1) 
 Change %  -2.4 (±14.7) -8.0 (±10.0) 
*P<0.05, *P<0.01, significantly different from baseline 
^Change % =                     X 100%.   week 12 – week 0 week 0 
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Figure 2 The mean (±SEM) percentage change in serum lipids from baseline to the end of the 12 
week dietary intervention.   
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